Goldman Sachs’s Structure Therapeutics GPCR Stock Holding History

Goldman Sachs’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.36M	Hold	173,500	–	–	﹤0.01%	3212
2025 Q4	$12.1M	Buy	+173,500	New	+$7.08M	﹤0.01%	2907
2025 Q2	–	Sell	-35,000	Closed	-$606K	–	6214
2025 Q1	$606K	Buy	+35,000	New	+$857K	﹤0.01%	5068
2024 Q4	–	Sell	-13,300	Closed	-$584K	–	6135
2024 Q3	$584K	Buy	+13,300	New	+$514K	﹤0.01%	4962

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs's GPCR Position: Q1 2026 in Review

Goldman Sachs increased its Structure Therapeutics (GPCR) stake by 16% in Q1 2026, buying an estimated $2.48M and bringing the position to 260,543 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2864.

Goldman Sachs first reported a position in GPCR in Q3 2023 and has held it in 11 quarters since. The position peaked at $31.3M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Goldman Sachs held 260,543 shares of Structure Therapeutics worth $12.6M as of Q1 2026.
Goldman Sachs bought 36,211 Structure Therapeutics shares in Q1 2026, an estimated $2.48M.
Structure Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2864 holding.
Goldman Sachs first reported a position in Structure Therapeutics in Q3 2023 and has held it in 11 quarters since.
Goldman Sachs's Structure Therapeutics position peaked at $31.3M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.